Enfortumab Vedotin Shows Promise for Urothelial Carcinoma Enfortumab Vedotin Shows Promise for Urothelial Carcinoma

The antibody-drug conjugate enfortumab vedotin is superior to chemotherapy in patients with previously treated advanced urothelial carcinoma, primary results of the EV-301 trial show.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news